Clinical

Dataset Information

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers


ABSTRACT: This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum-tolerated dose (MTD) or recommended dosage (RD) of ZW49, the investigational agent under study, and to assess the safety and tolerability of ZW49. Eligible patients include those with locally advanced (unresectable) or metastatic HER2-expressing cancers.

DISEASE(S): Ovarian Cancer,Colorectal Cancer,Non-small Cell Lung Cancer,Her2-expressing Cancers,Breast Cancer

PROVIDER: 2295671 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR